Rapid Micro Biosystems' Chief Operating Officer, John J. Addington Wilson, completed a sale of 5,403 Class A common shares on February 20, 2026. The shares were sold at $3.923 each, producing gross proceeds of approximately $21,195. According to the transaction disclosure, the sale was executed to satisfy tax obligations resulting from the vesting of restricted stock units.
Following the sale, Wilson directly holds 326,365 shares of Rapid Micro Biosystems. The insider transaction comes as the company's stock has experienced a notable rise - a 45% increase over the past six months - a move that InvestingPro's analysis suggests has left the shares trading above their Fair Value estimate.
Investors are also awaiting Rapid Micro Biosystems' next set of financial disclosures: the company is scheduled to report earnings on February 27. The timing places the insider sale roughly one week before the public release of quarterly results.
Recent reported financial performance
In a company press release, Rapid Micro Biosystems reported substantial revenue growth for the fourth quarter of 2025. Total revenue for the quarter is expected to be approximately $11.3 million, representing roughly 37% year-over-year growth. For the full year 2025 the company anticipates revenue of about $33.6 million, an increase of approximately 20% versus the prior year.
These figures were disclosed by the company and provide additional context to the insider sale and market movement in the weeks leading up to the firm's upcoming earnings report.
Context for readers
- The insider sale was explicitly undertaken to cover tax liabilities tied to vested restricted stock units.
- InvestingPro analysis characterizes the stock as currently overvalued relative to its Fair Value.
- Rapid Micro Biosystems has reported both quarterly and full-year revenue increases for 2025 and will report formal earnings on February 27.
This report presents the transaction details and the company-provided revenue outlook without further interpretation.